Press releases
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
More ▼
Key statistics
On Friday, Atara Biotherapeutics Inc (AT2:MUN) closed at 0.5034, 135.23% above the 52 week low of 0.214 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.5034 |
---|---|
High | 0.5034 |
Low | 0.5034 |
Bid | 0.4621 |
Offer | 0.4828 |
Previous close | 0.5102 |
Average volume | 456.60 |
---|---|
Shares outstanding | 120.42m |
Free float | 109.22m |
P/E (TTM) | -- |
Market cap | 61.53m USD |
EPS (TTM) | -2.12 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:04 BST.
More ▼